{"contained":[{"characteristic":[{"code":{"coding":[{"code":"age-range","system":"http://ema.europa.eu/example/characteristic"}]},"exclude":false,"valueRange":{"low":{"unit":"a","value":18}}}],"id":"group","membership":"definitional","resourceType":"Group","type":"person"}],"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/structuredefinition-wg","valueCode":"brr"}],"id":"example-indication","indication":{"diseaseStatus":{"concept":{"coding":[{"code":"Recurrent","system":"http://ema.europa.eu/example/diseasestatus"}]}},"diseaseSymptomProcedure":{"concept":{"coding":[{"code":"Pulmonary-embolism-and-thrombosis-example-code","system":"http://ema.europa.eu/example/indicationasdisease-symptom-procedure"}],"text":"Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults."}},"intendedEffect":[{"concept":{"coding":[{"code":"PRYLX","system":"http://ema.europa.eu/example/intendedeffect"}]}}]},"population":[{"reference":"#group"}],"resourceType":"ClinicalUseDefinition","subject":[{"reference":{"reference":"MedicinalProductDefinition/example"}}],"type":"indication"}